| セッション情報 | International Forum 2(Liver) 4.Treatment Strategy |
|---|---|
| タイトル | IF2-4-IV (Plenary presentation) Treatment Strategy of Hepatocellular Carcinoma |
| 演者 | Ryosuke Tateishi（Department of GastroenterologyThe University of Tokyo Hospital） |
| 共同演者 | Shuichiro Shiina（Department of GastroenterologyThe University of Tokyo Hospital）, Takamasa Ohki（Department of GastroenterologyThe University of Tokyo Hospital）, Takahisa Sato（Department of GastroenterologyThe University of Tokyo Hospital）, Ryota Masuzaki（Department of GastroenterologyThe University of Tokyo Hospital）, Jun Imamura（Department of GastroenterologyThe University of Tokyo Hospital）, Tadashi Goto（Department of GastroenterologyThe University of Tokyo Hospital）, Hideo Yoshida（Department of GastroenterologyThe University of Tokyo Hospital）, Shuntaro Obi（Department of GastroenterologyThe University of Tokyo Hospital）, Keisuke Hamamura（Department of GastroenterologyThe University of Tokyo Hospital）, Haruhiko Yoshida（Department of GastroenterologyThe University of Tokyo Hospital）, Masao Omata（Department of GastroenterologyThe University of Tokyo Hospital） |
| 抄録 | Current options fbr the treatment of hepatocellular carcinoma（HCC）consist of surgical resectionor－thotropic liver transplantationtranscatheter arterial chemoembolization （TACE）and percutaneous abla－tion． Among themradiofrequency ablation （RFA） is rapidly gaining use worldwide because of its higherability for local cure than ethanol inj ection as resection is indicated for 20－300／o of nai’ve patients becauseof underlying chronic liver diseases based on hepatitis B or C virus infection． Percutaneous ablation is gen－erally indicated for those with three or fewer lesionsall of which are 3 cm or less in diameter． Howeverwe also performed RFA on patients beyond these criteria if the procedure could be assumed to be clini－cally effective． Our retrospective cohort study with Cox proportional hazard regression revealed that theprognosis of patients with HCC deteriorated with increasing size and number of nodules． However therewere no definite threshold on the size and number of nodules． Patients with HCC are frequently encoun－tered by recurrence even after curative resection． RFA could be performed approximately 900／o of pa－tients with recurrent HCC at our institution． RFA can also be indicated to reduce the tumor burden incombination with TACE when it is difficult to ablate all nodules curatively because of multiplicity． An－other analysis showed that debulking of a tumor in the liver might improve the survival of patients withextrahepatic metastasis． ln conclusionwe place RFA at the heart of treatment strategy for HCCwhichcan improve the survival of the patients at various stage of the disease． |
| 索引用語 |